Search | WHO COVID-19 Research Database

1.

HER2 copy number variation in non-small cell lung cancer (NSCLC)

Tagliamento, M.; Auclin, E.; Valent, A.; Ferrara, R.; Cotteret, S.; Rouleau, E.; Caramella, C.; Riudavets Melia, M.; Gazzah, A.; Adam, J.; Jovelet, C.; Bayle, A.; Lacroix, L.; Auger, N.; Barlesi, F.; Planchard, D.; Besse, B.; Mezquita, L..

Annals of Oncology ; 33:S1050, 2022.

Article in English | EMBASE | ID: covidwho-2041544

2.

International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome

Hachem, R. Y.; Chaftari, A. M.; Masayuki, N.; Hamerschlak, N.; Dagher, H.; Jiang, Y.; Siddiqui, B.; Bayle, A.; Somer, R.; Cruz, A. F.; Gorak, E.; Bhinder, A.; Mori, N.; Datoguia, T.; Shelanski, S.; Dragvich, T.; Kiat, Y. E. V.; Fakhreddine, S.; Hanna, P. A.; Chemaly, R. F.; Mulanovich, V. E.; Adachi, J.; Borjan, J.; Khawaja, F.; Granwehr, B.; John, T.; Guevara, E. Y.; Torres, H. A.; Slavin, M.; Teh, B.; Subbiah, V.; Kontoyiannis, D. P.; Malek, A.; Raad, I. I..

Open Forum Infectious Diseases ; 8(SUPPL 1):S15, 2021.

Article in English | EMBASE | ID: covidwho-1746816

3.

Lung Cancer and Hematologic Malignancy ( HM) Patients Are Associated with the Highest Risk of Progressing to Severe Disease and Mortality in Cancer Patients with COVID-19

Chaftari, A. M.; Malek, A.; Dagher, H.; Jiang, Y.; Bayle, A.; Bhinder, A.; Cruz, A. F.; Siddiqui, B.; Somer, R.; Datoguia, T.; Slavin, M.; Dragvich, T.; Gorak, E.; Mori, N.; Hachem, R. Y.; Raad, I. I..

Open Forum Infectious Diseases ; 8(SUPPL 1):S254, 2021.

Article in English | EMBASE | ID: covidwho-1746700

4.

Impact of COVID-19 on ongoing oncological and hematological treatment strategy

Bayle, A.; Ouali, K.; Colomba, E.; Ibrahimi, N.; Foulon, S.; Gachot, B.; Willekens, C.; Stoclin, A.; Merad, M.; Griscelli, F.; Sun, R.; Ammari, S.; Michot, J. M.; André, F.; Scotté, F.; Besse, B.; Soria, J. C.; Barlesi, F.; Albiges, L.; Pommeret, F..

Annals of Oncology ; 32:S1159, 2021.

Article in English | EMBASE | ID: covidwho-1432924

5.

Sustained cancer clinical trial activity during the COVID-19 pandemic

Bayle, A.; Baldini, C.; Romano, P. M.; Michot, J. M.; Champiat, S.; Bahleda, R.; Gazzah, A.; Marabelle, A.; Verlingue, L.; Geraud, A.; Morel, D.; Michiels, S.; Ribrag, V.; Hollebecque, A.; Albiges, L.; Besse, B.; Soria, J. C.; Massard, C.; Barlesi, F.; Postel-Vinay, S..

Annals of Oncology ; 32:S1151, 2021.

Article in English | EMBASE | ID: covidwho-1432905

6.

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies.

Pommeret, F; Colomba, J; Bigenwald, C; Laparra, A; Bockel, S; Bayle, A; Michot, J-M; Hueso, T; Albiges, L; Tiberghien, P; Marot, S; Jary, A; Lacombe, K; Barlesi, F; Griscelli, F; Colomba, E.

Ann Oncol ; 32(11): 1445-1447, 2021 11.

Article in English | MEDLINE | ID: covidwho-1427516

Subject(s)

COVID-19 , Clinical Deterioration , Neoplasms , B-Lymphocytes , Humans , Mutation , SARS-CoV-2

7.

Severe COVID-19 in patients with hematological cancers presenting with viremia.

Michot, J M; Hueso, T; Ibrahimi, N; Pommeret, F; Willekens, C; Colomba, E; Francis, S; Bayle, A; Cournède, P H; Merad, M; Foulon, S; Albiges, L; Gachot, B; Barlesi, F; Soria, J C; Ribrag, V; Griscelli, F.

Ann Oncol ; 32(10): 1297-1300, 2021 10.

Article in English | MEDLINE | ID: covidwho-1306845

Subject(s)

COVID-19 , Hematologic Neoplasms , Hematologic Neoplasms/complications , Hospitalization , Humans , SARS-CoV-2 , Viremia/complications

8.

Comparing the outcome of COVID-19 in cancer and non-cancer patients: An international multicenter study

Hachem, R. Y.; Datoguia, T.; Siddiqui, B.; Fernandez Cruz, A.; Mori, N.; Fakhreddine, S.; Lee, D. G.; Gorak, E.; Somer, R.; Bhinder, A.; Shelanski, S.; Dragivich, T.; Bayle, A.; Chemaly, R. F.; Mulonovich, V.; Adachi, J.; Malek, A.; Slavin, M.; Jiang, Y.; Chaftari, A. M.; Raad, I. I..

Open Forum Infectious Diseases ; 7(SUPPL 1):S256, 2020.

Article in English | EMBASE | ID: covidwho-1185738

9.

Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments

Barlesi, F.; Foulon, S.; Bayle, A.; Gachot, B.; Pommeret, F.; Willekens, C.; Stoclin, A.; Merad, M.; Griscellil, F.; Micol, J. B.; Sun, R.; Nihouarn, T.; Balleygier, C.; Andre, F.; Scotte, F.; Besse, B.; Soria, J. C.; Albiges, L..

Cancer Research ; 80(16):2, 2020.

Article in English | Web of Science | ID: covidwho-1115174

10.

Outcome of older cancer patientsinfected with Covid19 at Gustave Roussy Cancer Center

Hauchecorne, M.; Baldini, C.; Foulon, S.; Bayle, A.; Gachot, B.; Pommeret, F.; Vincent, H.; Lamy, T.; Nagera, C.; Willekens, C.; Griscelli, F.; Netzer, F.; Balleyguier, C.; Ammari, S.; Andre, F.; Scotte, F.; Besse, B.; Soria, J. C.; Barlesi, F.; Albiges, L..

Clinical Cancer Research ; 26(18 SUPPL), 2020.

Article in English | EMBASE | ID: covidwho-992022

11.

Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center

Hauchecorne, M.; Baldini, C.; Foulon, S.; Bayle, A.; Gachot, B.; Pommeret, F.; Willekens, C.; Griscelli, F.; Netzer, F.; Balleyguier, C.; Ammari, S.; André, F.; Scotté, F.; Besse, B.; Soria, J. C.; Barlesi, F.; Albiges, L..

Annals of Oncology ; 31:S998, 2020.

Article in English | EMBASE | ID: covidwho-804937

Subject(s)

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL